Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives Average Rating of “Hold” from Brokerages

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) has received a consensus rating of “Hold” from the six brokerages that are presently covering the firm, Marketbeat reports. Six analysts have rated the stock with a hold rating. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $35.00.

A number of research firms have weighed in on CALT. HC Wainwright restated a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Lifesci Capital lowered shares of Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Citigroup reiterated a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research note on Friday, May 31st. Stifel Nicolaus restated a “hold” rating and set a $40.00 price objective (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $39.00 target price (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th.

Calliditas Therapeutics AB (publ) Stock Performance

Shares of CALT opened at $38.75 on Tuesday. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -20.95 and a beta of 1.77. Calliditas Therapeutics AB has a 12 month low of $15.25 and a 12 month high of $41.90. The firm has a fifty day simple moving average of $29.92 and a 200 day simple moving average of $24.97. The company has a current ratio of 2.69, a quick ratio of 2.62 and a debt-to-equity ratio of 8.46.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last posted its quarterly earnings data on Thursday, May 23rd. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74). The business had revenue of $28.43 million for the quarter, compared to analyst estimates of $35.78 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. Research analysts forecast that Calliditas Therapeutics AB will post -0.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 980 shares of the company’s stock, valued at approximately $25,000. 2.83% of the stock is owned by institutional investors.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.